| Literature DB >> 27566066 |
Zaynab Al-Eisawi1,2, Philip Beale3, Charles Chan4, Jun Qing Yu1, Nicholas Proschogo5, Mark Molloy6, Fazlul Huq7,8.
Abstract
BACKGROUND: The management of ovarian cancer remains a challenge. Because of the lack of early symptoms, it is often diagnosed at a late stage when it is likely to have metastasized beyond ovaries. Currently, platinum based chemotherapy is the primary treatment for the disease. However acquired drug resistance remains an on-going problem. As cisplatin brings about apoptosis by intrinsic and extrinsic pathways, this study aimed to determine changes in activity of platinum drugs when administered in two aliquots as against a bolus and sought to determine association with changes in GSH, speciation of platinum drugs and changes in protein expression.Entities:
Keywords: Aging effect; Carboplatin (CB); Cisplatin (CS); Drug combination; Drug resistance; Drug uptake; Oxaliplatin (OX); Synergism
Mesh:
Substances:
Year: 2016 PMID: 27566066 PMCID: PMC5002105 DOI: 10.1186/s12885-016-2731-1
Source DB: PubMed Journal: BMC Cancer ISSN: 1471-2407 Impact factor: 4.430
Fig. 1Chemical structures of cisplatin, carboplatin and oxaliplatin
Human ovarian cancer cell lines used in this study
| Cell line | Phenotype |
|---|---|
| A2780 | Untreated ovarian tumour |
| A2780cisR | CS resistant ovarian tumour |
| A2780ZD0473R | ZD0473a resistant ovarian tumour |
| SKOV-3 | Oestrogen receptor positive ovarian tumour |
aZD0473 (also known as JM473 and AMD 473) is a sterically hindered platinum complex with a cis-geometry like cisplatin
Fig. 2Cell growth inhibition following increasing concentrations of platinum drugs. Cell survival fractions of ovarian cancer A2780, A2780cisR, A2780ZD0473R and SKOV-3 cell lines following treatment with increasing concentrations of a CS, b CB and c OX for 72 h were determined using MTT assay and spectrophotometric measurement. Error bars represent the standard deviation (where straight lines or curves containing the dot points are meaningless)
Summary of the IC50 values (μM) and resistance factors (RF) for CS, CB and OX as applied to the ovarian cancer A2780, A2780cisR, A2780ZD0473R and SKOV-3 cell lines. IC50 is the drug concentration required for 50 % cell kill and RF is the ratio of the IC50 value in the resistant A2780cisR and A2780ZD0473R cell lines over that in the responsive parent A2780 cell line
| A2780 | A2780cisR | RF | A2780ZD0473R | RF | SKOV-3 | |
|---|---|---|---|---|---|---|
| CS | 0.5 ± 0.03 | 8.2 ± 0.6 | 17.7 | 6.0 ± 0.5 | 13.0 | 10.2 ± 0.5 |
| CB | 14.0 ± 1.4 | 48.9 ± 3.9 | 3.5 | 64.6 ± 3.2 | 4.6 | 43.4 ± 3.9 |
| OX | 0.2 ± 0.01 | 0.4 ± 0.02 | 1.9 | 0.4 ± 0.03 | 2.1 | 43.6 ± 3.0 |
Fig. 3Combination Index (CI) values following the administration of a CS, b CB and c OX in two aliquots with a time gap of 2, 4, 8, or 24 h as applied to the ovarian cancer A2780, A2780cisR, A2780ZD0473R and SKOV-3 cell lines using both fresh/fresh and fresh/aged combinations. CI values were calculated following 72 h treatments. CI values of <1, =1 and >1 indicate respectively synergism, additivity and antagonism in combined drug action
Fig. 4Cellular platinum accumulation in ovarian cancer A2780 and A2780cisR cell lines resulting from administration of CS in two aliquots using both fresh/fresh and fresh/aged combinations of CS with a time gap of 2 and 4 h. Cells were treated with the drugs for 24 h followed by collection, lysis and finally Pt was determined using AAS. Data was statistically analyzed using the paired Student’s t test: * p < 0.05 indicates significant difference from control. Error bars represent the standard deviation
Fig. 5Platinum − DNA binding in ovarian cancer A2780 and A2780cisR cell lines as applied to the administration of CS in two aliquots using both fresh/fresh and fresh/aged combinations of CS with a time gap of 2 and 4 h. Cells were treated with the drugs for 24 h followed by collection, DNA extraction and finally pt detection using AAS. Data was statistically analyzed using the paired Student’s t test: * p < 0.05 indicates significant difference from control. Error bars represent the standard deviation
Fig. 6Levels of a total glutathione (GSH plus GSSG) and b oxidized glutathione (GSSG) in relative luminescence units (RLU × 104) in A2780 and A2780cisR cells before and after their treatments with solutions of CS and CB administered as a bolus and in two aliquots with time gaps of 2 and 4 h using fresh/fresh and fresh/aged combinations. Cells were treated for 24 h and glutathione content was determined using GSH/GSSG-Glo Assay kit. Data was statistically analyzed using the paired Student’s t test: * p < 0.05 indicates significant difference from control. Error bars represent the standard deviation
Fig. 7Magnified mass spectrum showing major peaks of OX dissolved in cell culture medium. The 543.1 peak is the base peak due to the cell culture medium
Major peaks in the mass spectra of aged solution of OX in cell media
| m/z | No. of possibilities | Formula | Relative intensity (×106) | Suggested structure |
|---|---|---|---|---|
| 398 | 1 | Pt(C6H14N2)(C2O4) | 16 |
|
| 420.0493 | 4 | [Pt(C6H14N2)(C2O4) + Na]+ | 4.6 |
|
| 436.0233 | 2 | Pt(C6H14N2)2 – 3H | 7.2 |
|
| 478.0080 | 14 | [Pt(C6H14N2)(C8H11NO3)]+ | 8 |
|
| 680.1303 | 67 | [Pt(C6H14N2)(C10H17N3O6S)(CH3CH2SH) + 2H]+ | 26 |
|
| 738.0889 | 157 | [Pt(C6H14N2)(C10H17N3O6S)(C3H7NO2S)]+ | 9 |
|
| 795.0480 | 277 | [Pt2(C6H14N2)2(C2O4)2 + H]+ | 21 |
|
| 940.2129 | 377 | [Pt(C6H14N2)(C10H17N3O6S)2O]+ | 19 |
|
Fig. 82-DE pattern of whole-cell proteins in A2780 cell line. The 2-D gel was stained with coomasiee brilliant blue (11 cm, pH 3–10 non-linear, 4–20 % SDS-PAGE, 200 μg proteins). The protein spots differentially expressed in A2780cisR compared to the parent A2780 cell line identified in this study are marked with their spot number ID
In total, 22 proteins with differential expression (2-fold increase or decrease, ANOVA p < 0.05) between A2780cisR and the parent A2780 cell line due to treatment with CS in two aliquots with a time gap of 2 h using fresh/fresh and fresh/aged combinations were identified by MALDI-TOF/TOF
| Spot | ID | Full name | MALDI | location | Expression in A2780cisR | Post treatment expression | Function | Tumour association | ||
|---|---|---|---|---|---|---|---|---|---|---|
| CS | CS + CS | |||||||||
|
|
| |||||||||
| 3 | COX5A | Cytochrome c oxidase subunit 5A, mitochondrial | Score: 63 | Mitochondria | Down Regulated | PR | PR | OR | Ribosome biogenesis; mitochondrial respiratory chain | Breast [ |
| 19 | COF2 | Cofilin‐2 | Score: 127 | Cytoplasm, cytoskeleton | Down Regulated | R | R | OR | Actin polymerization | Pancreatic [ |
| 34 | 1433G | 14‐3‐3 protein gamma | Score: 315 | Cytoplasm | Down Regulated | PR | PR | OR | Adapter protein | Breast [ |
| 41 | MARE1 | Microtubule‐associated protein RP/EB family member 1 | Score: 62 | Cytoplasm | Down Regulated | - | R | OR | Microtubule cytoskeleton dynamics; cell migration. | Colon [ |
| 50 | NPM | Nucleophosmin | Score: 68 | Nucleoplasm | Down Regulated | - | R | OR | Chaperone; ribosome biogenesis; p53 and ARF regulation | Bladder [ |
| 51 | ANXA1 | Annexin A1 | Score: 369 | Nucleus, cytoplasm | Down Regulated | R | R | OR | Calcium/phospholipid-binding protein | breast [ |
| 62 | RSSA | 40S ribosomal protein SA | Score: 311 | Cell membrane, cytoplasm, nucleus | Up Regulated | R | R | - | laminin receptor; fate determination; tissue morphogenesis | Breast [ |
| 65 | ACTB | Actin, cytoplasmic 1 | Score: 767 | Cytoplasm | Up Regulated | PR | R | PR | cell motility | Colon [ |
| 70 | CALU | Calumenin | Score: 141 | Sarcoplasmic, endoplasmic reticulum | Up Regulated | - | OR | PR | Vitamin K-dependent carboxylation | Colon [ |
| 72 | HNRPF | Heterogeneous nuclear ribonucleoprotein F | Score: 342 | Nucleus | Down Regulated | R | OR | R | processing of pre-mRNAs; alternative splicing events | Gastric [ |
| 76 | ENOA | Alpha‐enolase | Score: 471 | Cytoplasm | Down Regulated | - | PR | R | Glycolysis; hypoxia tolerance; tumour suppressor | Breast [ |
| 85 | ATPA | ATP synthase subunit alpha, mitochondrial | Score: 391 | Mitochondria | Up Regulated | - | OR | OR | Production of ATP from ADP | Breast [ |
| 92 | PDIA3 | Protein disulfide-isomerase A3 | Score: 525 | Endoplasmic reticulum | Down Regulated | PR | PR | R | endopeptidase; electron carrier; | Lung [ |
| 100 | HNRPK | Heterogeneous nuclear ribonucleoprotein K | Score: 123 | Cytoplasm, nucleus | Up Regulated | - | OR | - | Pre-mRNA-binding proteins; p53 response to DNA damage | Breast [ |
| 103 | CH60 | 60 kDa heat shock protein, mitochondrial | Score: 762 | Mitochondria | Up Regulated | PR | OR | PR | macromolecular assembly; stress working chaperone | Bronchus [ |
| 104 | TCPQ | T‐complex protein 1 subunit theta | Score: 200 | Cytoplasm | Down Regulated | R | OR | R | chaperone | Colon [ |
| 127 | GRP75 | Stress‐70 protein, mitochondrial | Score: 839 | Mitochondria, nucleus | Down Regulated | R | PR | R | Cell proliferation; cellular aging; chaperone | Brain, Breast, colon, kidney, lung, ovarian [ |
| 139 | GLU2B | Glucosidase 2 subunit beta | Score: 80 | Endoplasmic reticulum | Up Regulated | OR | OR | - | Regulatory subunit of glucosidase II | Colon [ |
| 149 | HSP74 | Stress‐70 protein, mitochondrial | Score: 187 | Cytoplasm | Down Regulated | - | OR | PR | Stress response; cell proliferation, differentiation | Breast [ |
| 170 | HNRPC | Heterogeneous nuclear ribonucleoproteins | Score: 142 | Nucleus | Up Regulated | - | R | OR | mRNA processing and translation | Breast [ |
| 215 | CALR | Calreticulin | Score: 246 | Endoplasmic, sarcoplasmic reticulum | Up Regulated | - | R | OR | Calcium-binding chaperone | Bladder [ |
| 246 | VIME | Vimentin | Score: 539 | Cytoplasm | Up Regulated | P | OR | - | Filaments attached to nucleus and endoplasmic reticulum | Breast [ |
(−) indicates that the spot was either not visible on the gel or that the treatment had no effect on the expression of the protein
R Restored, PR Partially Restored, OR Over Restored
Fig. 9Grouping of proteins and enzymes based on the cellular functions that were found to be differentially expressed in the resistant A2780cisR cell line as compared to the parent A2780 cell line and that have undergone further changes in expression after treatment with the administration of CS in two aliquots
Summary of results following treatment of A2780cisR cell line with CS administered in two aliquots with 2 h time gap
| Cytotoxic effect | Cellular accumulation | DNAbinding | Proteomicsa | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Fresh | Aged | Fresh | Aged | Fresh | Aged | Fresh | Aged | |||
|
| ||||||||||
| 2 h | Antagonistic | Synergistic | Unchanged | Increased | Increased | Greater increase |
| (D,R), |
| (D,OR), |
aThe proteins listed have been fully/over restored in A2780cisR due to the selected combinations as compared to the parent A2780 cell line. Keys: U = up-regulated, D = down-regulated, OR = over-restored, R = fully-restored
Fig. 10Venn diagram listing the proteins expressed in A2780cisR cells that were restored or over restored compared to the levels found in A2780 cells after treatment of cells with aged (synergistic) and fresh (antagonistic) solutions of CS in two aliquots with 2 h time gap